Article Text

Download PDFPDF
Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle
  1. L Cheng1,
  2. E Anglin2,
  3. F Cunin3,
  4. D Kim2,
  5. M J Sailor2,
  6. I Falkenstein1,
  7. A Tammewar1,
  8. W R Freeman1
  1. 1
    Jacobs Retina Center at Shiley Eye Center, UCSD, La Jolla, CA, USA
  2. 2
    Department of Chemistry and Biochemistry, UCSD, La Jolla, CA, USA
  3. 3
    Laboratoire de Matériaux Catalytiques et Catalyse en Chimie Organique, UMR5618 ENSCM-CNRS-UMI, Institut Gerhardt, Montpellier, France
  1. Dr L Cheng, Jacobs Retina Center at Shiley Eye Center, UCSD, 9415 Campus Point Drive, La Jolla, CA 92037-0946, USA; cheng{at}


Aim: To determine the suitability of porous silicon photonic crystals for intraocular drug-delivery.

Methods: A rugate structure was electrochemically etched into a highly doped p-type silicon substrate to create a porous silicon film that was subsequently removed and ultrasonically fractured into particles. To stabilise the particles in aqueous media, the silicon particles were modified by surface alkylation (using thermal hydrosilylation) or by thermal oxidation. Unmodified particles, hydrosilylated particles and oxidised particles were injected into rabbit vitreous. The stability and toxicity of each type of particle were studied by indirect ophthalmoscopy, biomicroscopy, tonometry, electroretinography (ERG) and histology.

Results: No toxicity was observed with any type of the particles during a period of >4 months. Surface alkylation led to dramatically increased intravitreal stability and slow degradation. The estimated vitreous half-life increased from 1 week (fresh particles) to 5 weeks (oxidised particles) and to 16 weeks (hydrosilylated particles).

Conclusion: The porous silicon photonic crystals showed good biocompatibility and may be used as an intraocular drug-delivery system. The intravitreal injectable porous silicon photonic crystals may be engineered to host a variety of therapeutics and achieve controlled drug release over long periods of time to treat chronic vitreoretinal diseases.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding: (1) Unrestricted research fund to Jacobs Retina Center, UCSD (Freeman & Cheng). (2) Supported in part by Research to Prevent Blindness (Freeman). (3) National Science Foundation, Grant# DMR-0503006 (MJS). MJS is a member of the Moores UCSD Cancer Center and the UCSD NanoTUMOR Center under which this research was conducted and partially supported by NIH grant U54 CA 119335. The CNRS/DREI program (call for proposal CNRS/United States 2005 #3312) is also acknowledged for financial support.

  • Competing interests: UCSD has filed a provisional patent for this intraocular drug-delivery system.